This is a non-material pipeline update for a $1M market cap company. The collaboration validates MEAI's potential metabolic thesis but generates no new clinical data. Monitor for future preclinical results from this 12-month study — positive data could provide a near-term catalyst. Without disclosed study costs or financing, cash runway implications are unknown.
Price Chart
Executive Summary
Clearmind Medicine announced a preclinical research agreement with Hebrew University to study its lead compound MEAI (CMND-100) in combination with and as a maintenance therapy following tirzepatide in diet-induced obese mice. The 12-month study evaluates whether MEAI can prevent post-tirzepatide weight regain and enhance energy expenditure. This is an early-stage, hypothesis-generating collaboration with no financial terms disclosed and no clinical data — a routine pipeline update for a micro-cap preclinical biotech.
Key Facts
- Clearmind signed a research agreement with Yissum Research (Hebrew University) to fund a 12-month preclinical study of MEAI in combination/sequencing with tirzepatide in DIO mice.
- Prior collaboration showed MEAI alone achieved ~15–20% body weight reduction in DIO mice via increased energy expenditure.
- The study will test additive/synergistic effects of concurrent MEAI+tirzepatide and MEAI as maintenance therapy to prevent post-tirzepatide weight regain.
- No dollar amount, milestone payments, or financial terms of the research agreement were disclosed.
- No clinical data, IND filings, or patient enrollment were announced — study is preclinical only.
Financial Impact
No financial terms disclosed; agreement funds a preclinical academic study. No revenue or cost figures provided.
Risk Factors
- Preclinical data may not translate to human clinical results — high attrition rate for metabolic assets.
- No disclosed financial terms; research funding could pressure already limited cash reserves.
- CMND has a market cap of ~$1M and limited liquidity — any news can produce outsized price moves in either direction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-058410 |
| Document: ea0291277-6k_clearmind.htm | 0001213900-26-058410 |
| Document: 0001213900-26-058410-index-headers.html | 0001213900-26-058410 |
| Document: 0001213900-26-058410-index.html | 0001213900-26-058410 |
| Document: 0001213900-26-058410.txt | 0001213900-26-058410 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers